Validated Foundation. Expanding Frontier.

Validated Foundation. Expanding Frontier.

Our PurIST® pancreatic cancer test has been commercialized and clinically validated with Tempus. Three AACR 2026 posters show a path for ER, HER2, and HR status in liquid biopsy. 

ExpressCT™ – a Simple, Elegant and Integrated Liquid Biopsy Technology

ExpressCT™ – a Simple, Elegant and Integrated Liquid Biopsy Technology

Simultaneously collect the DNA alterations with your NGS assay while adding gene expression as another layer of data.

Extracting Gene Expression from ctDNA with Routine DNA Sequencing Workflows

Extracting Gene Expression from ctDNA with Routine DNA Sequencing Workflows

ExpressCT™ is a software layer that unlocks a new expression dimension from routinely generated NGS data including ER, HER2, molecular subtypes.

Finally, the power of gene expression in liquid biopsy

Finally, the power of gene expression in liquid biopsy

Gene expression brings a key dimension and addresses the limitations of DNA alteration focused liquid biopsies.

Finally, the full impact of liquid biopsy

ExpressCT™ is GeneCentric’s proprietary fragmentomics technology. It captures quantitative gene expression measurements directly from cfDNA sequencing data – the same data that CGP panels and most routine NGS workflows already generate. Now, expression-based biomarkers, such as ER status, HER2 expression, molecular subtypes, and ADC targets, can accompany the standard DNA mutation output. Built on more than a decade of research, ExpressCT™ brings a new dimension to minimally invasive blood testing and unlocks deeper, more dynamic biomarker data to power precision oncology.

LEARN MORE

Solutions & ExpressCT™

Our technology turns gene expression, whether from RNA-seq or ExpressCT™ fragmentomics of ctDNA, into tools that address unmet medical needs and advance cancer genomic profiling.

LEARN MORE

Partner

GeneCentric works with biopharma and diagnostics companies and commercial labs to bring gene expression into their programs. We translate promising science into faster development and better-defined patients. 

LEARN MORE
VIEW ALL RECENT NEWS & EVENTS